Extra Super Zhewitra is a medication that combines two active ingredients: vardenafil and dapoxetine. Vardenafil is used to treat erectile dysfunction (ED), while dapoxetine is used to treat premature ejaculation (PE). Like any medication, Extra Super Zhewitra can potentially cause side effects. Here are some common side effects associated with its use:
Headache: Headaches are one of the most common side effects reported with the use of Extra Super Zhewitra. These headaches can range from mild to moderate in intensity.
Nausea: Some individuals may experience feelings of nausea or upset stomach after taking Extra Super Zhewitra.
Dizziness: Dizziness or lightheadedness can occur, particularly when standing up from a sitting or lying position. This effect may be more pronounced if you're taking medications that lower blood pressure.
Flushing: Flushing or redness of the face and neck is another common side effect reported with the use of vardenafil-containing medications.
Nasal congestion: Some people may experience nasal congestion or a stuffy nose after taking Extra Super Zhewitra.
Vision changes: In rare cases, vardenafil-containing medications may cause changes in vision, such as blurred vision or sensitivity to light.
Priapism: Priapism is a rare but serious side effect characterized by a prolonged and painful erection lasting more than four hours. It requires immediate medical attention to prevent potential damage to the penis.
Hypotension: Extra Super Zhewitra can cause a temporary drop in blood pressure, especially if taken with other medications that lower blood pressure or with alcohol.
It's essential to talk to your healthcare provider before starting Extra Super Zhewitra, especially if you have any underlying medical conditions or are taking other medications. They can provide personalized guidance based on your individual health status and help monitor for any potential side effects. If you experience any severe or concerning side effects while taking Extra Super Zhewitra, seek medical attention promptly.
